Neeraj Agarwal

21.4k total citations · 5 hit papers
437 papers, 9.4k citations indexed

About

Neeraj Agarwal is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Neeraj Agarwal has authored 437 papers receiving a total of 9.4k indexed citations (citations by other indexed papers that have themselves been cited), including 324 papers in Pulmonary and Respiratory Medicine, 227 papers in Oncology and 123 papers in Cancer Research. Recurrent topics in Neeraj Agarwal's work include Prostate Cancer Treatment and Research (227 papers), Renal cell carcinoma treatment (84 papers) and Cancer Immunotherapy and Biomarkers (79 papers). Neeraj Agarwal is often cited by papers focused on Prostate Cancer Treatment and Research (227 papers), Renal cell carcinoma treatment (84 papers) and Cancer Immunotherapy and Biomarkers (79 papers). Neeraj Agarwal collaborates with scholars based in United States, France and United Kingdom. Neeraj Agarwal's co-authors include Kim N., Przemyslaw Twardowski, Umang Swami, Sumanta K. Pal, Oliver Sartor, Neal D. Shore, Karim Fizazi, Fred Saad, David Olmos and Joaquı́n Mateo and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Neeraj Agarwal

398 papers receiving 9.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib for Metastatic Castration-Resistant Prostate Cancer

2020 1.4k citations Fred Saad, Neal D. Shore et al. profile →
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

2019 891 citations Neeraj Agarwal, Anders Bjartell et al. profile →
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

2020 474 citations Fred Saad, Neal D. Shore et al. profile →
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

2021 351 citations Neeraj Agarwal et al. Journal of Clinical Oncology profile →
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

2021 285 citations Anders Bjartell, Axel S. Merseburger et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Neeraj Agarwal

Since Specialization

Citations

This map shows the geographic impact of Neeraj Agarwal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neeraj Agarwal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neeraj Agarwal more than expected).

Fields of papers citing papers by Neeraj Agarwal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neeraj Agarwal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neeraj Agarwal. The network helps show where Neeraj Agarwal may publish in the future.

Co-authorship network of co-authors of Neeraj Agarwal

This figure shows the co-authorship network connecting the top 25 collaborators of Neeraj Agarwal. A scholar is included among the top collaborators of Neeraj Agarwal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neeraj Agarwal. Neeraj Agarwal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer 2025 ·Clinical Cancer Research ·(unknown), Ryon P. Graf, (unknown), (unknown), Nicolas Sayegh, Gerald Li, Benjamin L. Maughan, Emmanuel S. Antonarakis, Rana R. McKay, Neeraj Agarwal, Umang Swami	0
2	Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancer 2025 ·The Oncologist ·Rana R. McKay, Shayan Nazari, Andrew Elliott, Jennifer R. Ribeiro, Brent S. Rose, Pedro C. Barata, Deepak Kilari, Rohan Garje, Neeraj Agarwal, Norm D. Smith, Emmanuel S. Antonarakis, Aditya Bagrodia, Himisha Beltran	0
3	Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial 2024 ·BMC Cancer ·Adriana M. Coletta, (unknown), (unknown), Sarah Taylor, (unknown), Pamela A. Hansen, Vinay Mathew Thomas, Cornelia M. Ulrich, Manish Kohli, Jonathan Chipman, Umang Swami, Sumati Gupta, Benjamin L. Maughan, Neeraj Agarwal	1
4	PD09-05 DIFFERENCES IN GENOMIC, TRANSCRIPTOMIC AND IMMUNE LANDSCAPE OF PROSTATE CANCER (PCA) BASED ON SITE OF METASTASIS (METS) 2024 ·The Journal of Urology ·Dhruv Puri, Umang Swami, Georges Gebrael, Shayan Nazari, Andrew Elliott, Chadi Nabhan, Rana R. McKay, Emmanuel S. Antonarakis, Aditya Bagrodia, Neeraj Agarwal	1
5	Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma 2024 ·Annals of Oncology ·Neeraj Agarwal, James Brugarolas, Pooja Ghatalia, S. George, John B.A.G. Haanen, Howard Gurney, Rahul Ravilla, (unknown), Benoit Beuselinck, И. А. Покатаев, Britt B.M. Suelmann, Mark Tuthill, Daniel A. Vaena, Flora Zagouri, Jane Wu, (unknown), (unknown), (unknown), M.B. Atkins	6
6	Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer 2024 ·Frontiers in Medicine ·Neal D. Shore, Joan Carles, Ray McDermott, Neeraj Agarwal, Bertrand Tombal	1
7	Differential Tumor Gene Expression Profiling of Patients With Prostate Adenocarcinoma on the Basis of BMI 2024 ·JCO Precision Oncology ·Vinay Mathew Thomas, (unknown), Georges Gebrael, Nicolas Sayegh, Nishita Tripathi, Roberto Nussenzveig, Yeonjung Jo, (unknown), (unknown), (unknown), Kamal Kant Sahu, (unknown), Benjamin L. Maughan, Neeraj Agarwal, Umang Swami	1
8	CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). 2024 ·Journal of Clinical Oncology ·Neeraj Agarwal, Arun Azad, Joan Carles, Nobuaki Matsubara, Stéphane Oudard, Fred Saad, Axel S. Merseburger, Andrey Soares, Bradley A. McGregor, Bogdan Żurawski, Scott North, Marinos Tsiatas, Igor Bondarenko, (unknown), (unknown), Keerti Vardhan Sharma, (unknown), Roberta Ferraldeschi, Fong Wang, Sumanta K. Pal	20
9	Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens 2024 ·The Oncologist ·Eddy Saad, Georges Gebrael, (unknown), (unknown), Renée Maria Saliby, Chris Labaki, Nicolas Sayegh, J. Connor Wells, Kosuke Takemura, (unknown), (unknown), Naveen S. Basappa, Lori Wood, Thomas Powles, D. Scott Ernst, Aly‐Khan A. Lalani, Neeraj Agarwal, Wanling Xie, Daniel Y.C. Heng, Toni K. Choueiri	0
10	Effectiveness of ChatGPT 4.0 in Telemedicine-Based Management of Metastatic Prostate Carcinoma 2024 ·Diagnostics ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Georges Gebrael, Neeraj Agarwal, Umang Swami, (unknown)	1
11	Access to Care and Healthcare Quality Metrics for Patients with Advanced Genitourinary Cancers in Urban versus Rural Areas 2023 ·Cancers ·Haoran Li, Kamal Kant Sahu, (unknown), Nishita Tripathi, Nicolas Sayegh, (unknown), (unknown), Sumati Gupta, Benjamin L. Maughan, Neeraj Agarwal, Umang Swami	1
12	Update on combined immunotherapy for the treatment of advanced renal cell carcinoma 2023 ·Human Vaccines & Immunotherapeutics ·Georges Gebrael, Kamal Kant Sahu, Neeraj Agarwal, Benjamin L. Maughan	20
13	1786P Effect of rapid ultra-low prostate-specific antigen decline (UL PSA) in TITAN patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) who received apalutamide (APA) plus androgen deprivation therapy (ADT) 2023 ·Annals of Oncology ·Axel S. Merseburger, Neeraj Agarwal, Anders Bjartell, Hiroji Uemura, (unknown), Amitabha Bhaumik, Juergen Boehm, Nguyen Toan Tran, (unknown), (unknown), Suneel Mundle, (unknown), Shane McCarthy, K.N. Chi, S. Chowdhury	2
14	Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer 2023 ·JAMA Network Open ·Nicolas Sayegh, Umang Swami, Yeonjung Jo, Georges Gebrael, Benjamin Haaland, Shilpa Gupta, Melissa Plets, Maha Hussain, David I. Quinn, Primo N. Lara, Ian M. Thompson, Neeraj Agarwal	5
15	External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer 2022 ·Molecular Cancer Therapeutics ·Umang Swami, Nicolas Sayegh, Yeonjung Jo, Benjamin Haaland, Taylor Ryan McFarland, Roberto Nussenzveig, (unknown), Deepika Sirohi, Andrew W. Hahn, Benjamin L. Maughan, Amir Goldkorn, Neeraj Agarwal	5
16	Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216) 2022 ·Journal of Clinical Oncology ·Neeraj Agarwal, Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Melissa Plets, Primo N. Lara, Andrea Harzstark, Przemyslaw Twardowski, Channing J. Paller, Dylan M. Zylla, Matthew R. Zibelman, Ellis Levine, Bruce J. Roth, Amir Goldkorn, Daniel A. Vaena, Manish Kohli, Tony Crispino, Nicholas J. Vogelzang, Ian M. Thompson, David I. Quinn	30
17	A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancers 2022 ·Heliyon ·(unknown), Kamal Kant Sahu, (unknown), (unknown), Nicolas Sayegh, Nishita Tripathi, Vinay Mathew Thomas, Sumati Gupta, Benjamin L. Maughan, Neeraj Agarwal, Umang Swami	2
18	Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma 2018 ·Clinical Genitourinary Cancer ·Andrew W. Hahn, (unknown), (unknown), Nityam Rathi, Erin Bailey, David D. Stenehjem, Neeraj Agarwal	34
19	First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies 2015 ·Clinical Cancer Research ·Pamela N. Münster, Rahul Aggarwal, David S. Hong, Jan H.M. Schellens, Ruud van der Noll, Jennifer M. Specht, Petronella O. Witteveen, Theresa L. Werner, Elizabeth Claire Dees, Emily K. Bergsland, Neeraj Agarwal, Joseph F. Kleha, M. Durante, Laurel M. Adams, Deborah A. Smith, Thomas A. Lampkin, Shannon R. Morris, Razelle Kurzrock	83
20	Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer 2013 ·Clinical Cancer Research ·Johanna C. Bendell, Michael S. Gordon, Herbert I. Hurwitz, Suzanne F. Jones, David S. Mendelson, Gerard C. Blobe, Neeraj Agarwal, Carolyn H. Condon, Dawn Wilson, Amelia E. Pearsall, Yijun Yang, Ty McClure, Kenneth M. Attie, Matthew L. Sherman, Sunil Sharma	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact